Chimeric Therapeutics (CHM) Status Update summary

Clinical trial progress and results

• Four phase I clinical trials are active in the U.S., with significant data and multiple updates expected in the next 12 months.

• The CDH17 CAR-T trial is recruiting at four US sites, with patient demand exceeding budget capacity and five on the waiting list.

• Seven successful manufacturing runs have been completed, and patients 8-10 are entering screening.

• Dose Level 1 showed stable disease in two patients, minor progression in one, and expected progression in another, with no off-target effects observed.

• FDA clearance was obtained to proceed to Dose Level 2 (150 million cells), with three patients ready for dosing and 28-day monitoring.

CHM CORE-NK and ADVENT-AML updates

• The ADVENT-AML trial at MD Anderson is progressing, with two of three patients achieving a complete response with incomplete blood count recovery.

• The response rate in this small group is 66%, higher than the typical 33% for standard care.

• CHM CORE-NK is an off-the-shelf NK cell therapy with ongoing Phase 1B trials in AML and CRC, showing no cytokine release syndrome or GvHD.

• NK cells remain active for 60-90 days, and additional patients are being dosed as momentum builds.

• Partner institutions MD Anderson and Case Western are supporting the majority of trial costs.

Financial and operational update

• Recent capital raises include a $4 million non-dilution grant and AUD 6.6 million from institutional investors, improving financial stability.

• Operational costs have been significantly reduced, with a lean team of four experts and minimal outsourcing.

• Most spending is focused on generating clinical data, with 60% allocated to the CDH17 program.

• The board and team have taken pay cuts to support budget constraints.

• Market cap approximately $1.6B with IPO in 2021.